{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:37:11Z","timestamp":1794591431556,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Spero Therapeutics","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Spero Therapeutics","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Complicated urinary tract infection (cUTI) is common among hospitalized patients. Though carbapenems are an effective treatment in the face of rising resistance, overuse drives carbapenem resistance (CR). We hypothesized that resistance to routinely used antimicrobials is common, and, despite frequent use of carbapenems, associated with an increased risk of inappropriate empiric treatment (IET), which in turn worsens clinical outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective cohort study of patients hospitalized with a culture-positive non-CR cUTI. Triple resistance (TR) was defined as resistance to <jats:underline>&gt;<\/jats:underline>\u20093 of the following: 3rd generation cephalosporins, fluoroquinolones, trimethoprim-sulfamethoxazole, fosfomycin, and nitrofurantoin. Multivariable models quantified the impact of TR and inappropriate empiric therapy (IET) on mortality, hospital LOS, and costs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 23,331 patients with cUTI, 3040 (13.0%) had a TR pathogen. Compared to patients with non-TR, those with TR were more likely male (57.6% vs. 47.7%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), black (17.9% vs. 13.6%, p\u2009&lt;\u20090.001), and in the South (46.3% vs. 41.5%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Patients with TR had higher chronic (median [IQR] Charlson score 3 [2, 4] vs. 2 [1, 4], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and acute (mechanical ventilation 7.0% vs. 5.0%, p\u2009&lt;\u20090.001; ICU admission 22.3% vs. 18.6%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) disease burden. Despite greater prevalence of empiric carbapenem exposure (43.3% vs. 16.2%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), patient with TR were also more likely to receive IET (19.6% vs. 5.4%, p\u2009&lt;\u20090.001) than those with non-TR. Although mortality was similar between groups, TR added 0.38 (95% CI 0.18, 0.49) days to LOS, and $754 (95% CI $406, $1103) to hospital costs. Both TR and IET impacted the outcomes among cUTI patients whose UTI was not catheter-associated (CAUTI), but had no effect on outcomes in CAUTI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>TR occurs in 1 in 8 patients hospitalized with cUTI. It is associated with an increase in the risk of IET exposure, as well as a modest attributable prolongation of LOS and increase in total costs, particularly in the setting of non-CAUTI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-05842-0","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T22:50:31Z","timestamp":1612824631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013\u20132018: a retrospective cohort study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-9761","authenticated-orcid":false,"given":"Marya D.","family":"Zilberberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Nathanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Sulham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"5842_CR1","unstructured":"Hospital Compare. Medicare.gov: The Official US Government Site for Medicare. Available at https:\/\/www.medicare.gov\/hospitalcompare\/Data\/Data-Updated.html#. Accessed 31 May 2019."},{"key":"5842_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.7326\/0003-4819-150-12-200906160-00013","volume":"150","author":"S Saint","year":"2009","unstructured":"Saint S, Meddings JA, Calfree D, Kowalski CP, Krein SL. Catheter-associated urinary tract infection and the Medicare rule changes. Ann Int Med. 2009;150:877\u201384.","journal-title":"Ann Int Med"},{"issue":"1","key":"5842_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/668770","volume":"34","author":"DM Sievert","year":"2013","unstructured":"Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. National Healthcare Safety Network (NHSN) team and participating NHSN facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1\u201314.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"5842_CR4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1086\/671740","volume":"34","author":"MD Zilberberg","year":"2013","unstructured":"Zilberberg MD, Shorr AF. Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect Control Hosp Epidemiol. 2013;34:940\u20136.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"5842_CR5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.ijantimicag.2006.02.009","volume":"27","author":"GG Zhanel","year":"2006","unstructured":"Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnoweski B, NAUTICA Group. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the north American urinary tract infection collaborative Alliance (NAUTICA). Int J Antimicrob Agents. 2006;27:468\u201375.","journal-title":"Int J Antimicrob Agents"},{"key":"5842_CR6","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1128\/AAC.06060-11","volume":"56","author":"GV Sanchez","year":"2012","unstructured":"Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother. 2012;56:2181\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"5842_CR7","doi-asserted-by":"publisher","first-page":"976273","DOI":"10.1155\/2012\/976273","volume":"2012","author":"A Dalhoff","year":"2012","unstructured":"Dalhoff A. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis. 2012;2012:976273.","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"5842_CR8","unstructured":"US Department of Health and Human Services Office for Human Research Protections. Human Subject Regulations Decision Charts. Available at https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/decision-charts\/index.html; Accessed July 19, 2019."},{"issue":"8","key":"5842_CR9","doi-asserted-by":"publisher","first-page":"e00346","DOI":"10.1128\/AAC.00346-20","volume":"64","author":"MD Zilberberg","year":"2020","unstructured":"Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Antimicrobial Susceptibility and Cross-Resistance Patterns among Common Complicated Urinary Tract Infections in U.S. Hospitals, 2013 to 2018. Antimicrob Agents Chemother. 2020;64(8):e00346\u201320. https:\/\/doi.org\/10.1128\/AAC.00346-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"5842_CR10","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1017\/ice.2018.166","volume":"39","author":"MD Zilberberg","year":"2018","unstructured":"Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Development and validation of a bedside instrument to predict carbapenem resistance among gram-negative pathogens in complicated urinary tract infections. Infect Control Hosp Epidemiol. 2018;39:1112\u20134.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"5842_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087382","volume":"9","author":"MB Rothberg","year":"2014","unstructured":"Rothberg MB, Pekow PS, Priya A, Zilberberg MD, Belforti R, Skiest D, et al. Using highly detailed administrative data to predict pneumonia mortality. PLoS One. 2014;9(1):e87382.","journal-title":"PLoS One"},{"issue":"Suppl 3","key":"5842_CR12","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1086\/677829","volume":"35","author":"MB Rothberg","year":"2014","unstructured":"Rothberg MB, Haessler S, Lagu T, Lindenauer PK, Pekow PS, Priya A, et al. Outcomes of patients with healthcare-associated pneumonia: worse disease or sicker patients? Infect Control Hosp Epidemiol. 2014;35(Suppl 3):S107\u201315.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"5842_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/jhm.2199","volume":"9","author":"T Lagu","year":"2014","unstructured":"Lagu T, Stefan MS, Haessler S, Higgins TL, Rothberg MB, Nathanson BH, Hannon NS, Steingrub JS, Lindenauer PK. The impact of hospital-onset Clostridium difficile infection on outcomes of hospitalized patients with sepsis. J Hosp Med. 2014;9:411\u20137.","journal-title":"J Hosp Med"},{"key":"5842_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"5842_CR15","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1378\/chest.122.1.262","volume":"122","author":"M Iregui","year":"2002","unstructured":"Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262\u20138.","journal-title":"Chest"},{"key":"5842_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1378\/chest.08-0842","volume":"134","author":"MD Zilberberg","year":"2008","unstructured":"Zilberberg MD, Shorr AF, Micek MT, Mody SH, Kollef MH. Antimicrobial therapy escalation and hospital mortality among patients with HCAP: a single center experience. Chest. 2008;134:963\u20138.","journal-title":"Chest"},{"key":"5842_CR17","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1128\/AAC.00851-07","volume":"51","author":"ST Micek","year":"2007","unstructured":"Micek ST, Kollef KE, Reichley RM, et al. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007;51:3568\u201373.","journal-title":"Antimicrob Agents Chemother"},{"key":"5842_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/CCM.0b013e3181fa41a7","volume":"39","author":"AF Shorr","year":"2011","unstructured":"Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH. Inappropriate antibiotic therapy in gram-negative sepsis increases hospital length of stay. Crit Care Med. 2011;39:46\u201351.","journal-title":"Crit Care Med"},{"issue":"10","key":"5842_CR19","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1097\/01.CCM.0000181731.53912.D9","volume":"33","author":"N Safdar","year":"2005","unstructured":"Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med. 2005;33(10):2184\u201393.","journal-title":"Crit Care Med"},{"issue":"5","key":"5842_CR20","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1097\/01.CCM.0000063087.93157.06","volume":"31","author":"DK Warren","year":"2003","unstructured":"Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox MJ, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med. 2003;31(5):1312\u20137.","journal-title":"Crit Care Med"},{"issue":"6","key":"5842_CR21","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1378\/chest.122.6.2115","volume":"122","author":"J Rello","year":"2002","unstructured":"Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, et al. VAP outcomes scientific advisory group. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002;122(6):2115\u201321.","journal-title":"Chest"},{"issue":"5","key":"5842_CR22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1086\/651669","volume":"31","author":"MI Restrepo","year":"2010","unstructured":"Restrepo MI, Anzueto A, Arroliga AC, Afessa B, Atkinson MJ, Ho NJ, et al. Economic burden of ventilator-associated pneumonia based on Total resource utilization. Infect Control Hosp Epidemiol. 2010;31(5):509\u201315.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"5842_CR23","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1086\/648083","volume":"30","author":"MD Zilberberg","year":"2009","unstructured":"Zilberberg MD, Shorr AF, Micek ST, Hoban AP, Pham V, Doherty JA, Ramsey AM, Kollef MH. Epidemiology and outcomes of hospitalizations with complicated skin and skin structure infections: implications of healthcare associated infection risk factors. Infect Control Hosp Epidemiol. 2009;30:1203\u201310.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"5842_CR24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1378\/chest.09-0596","volume":"136","author":"MD Zilberberg","year":"2009","unstructured":"Zilberberg MD, Nathanson BH, Sadigov S, Higgins TL, Kollef MH, Shorr AF. Epidemiology and outcomes of Clostridium difficile-associated disease among patients on prolonged acute mechanical ventilation. Chest. 2009;136:752\u20138.","journal-title":"Chest"},{"key":"5842_CR25","first-page":"45","volume":"73","author":"JD Chalmers","year":"2016","unstructured":"Chalmers JD, Akram AR, Singanayagam A, Wilcox MH, Hill AT. Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia. J Inf Secur. 2016;73:45\u201353.","journal-title":"J Inf Secur"},{"key":"5842_CR26","doi-asserted-by":"publisher","first-page":"P2469","DOI":"10.1183\/09031936.00187811","volume":"40","author":"M Carrabba","year":"2012","unstructured":"Carrabba M, Zarantonello M, Formica S, Mellace L, Castaldi S, Cappellini MD, Fabio G. Pneumonia and Clostridium difficile infection: hospital acquired infection in a non-ICU department. Eur Respir J. 2012;40:P2469.","journal-title":"Eur Respir J"},{"issue":"5","key":"5842_CR27","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61\u2013e111.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05842-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-021-05842-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05842-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T22:51:58Z","timestamp":1612824718000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-05842-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5842"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-05842-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"30 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Because this study used already existing fully de-identified data, it was exempt from ethics review under US 45 CFR 46.101(b)4 [].","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}